Indeed, different radioimmunoconjugates of anti-CD45 are currently tested in clinical trials of aHSCT for AML, MDS, high-risk lymphoma and MM (Table 3) (78–80). The gene discussed is PTPRC; the disease is acute myeloid leukemia.